Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, making up 10 to 15 percent of all cases. It is a serious diagnosis, but one with a relatively favorable overall prognosis: the 10-year survival rate reaches about 74 percent across all stages. That said, ILC carries unique challenges that set it apart from the more common ductal breast cancer, including difficulty detecting it on imaging, a higher chance of needing repeat surgery, and a risk of recurrence that can extend 10 or even 20 years after the original diagnosis.
Understanding what makes ILC different helps put its seriousness in perspective. The outlook depends heavily on the stage at diagnosis, the tumor’s biology, and how it responds to treatment.
What Makes ILC Different From Other Breast Cancers
The defining feature of ILC is the loss of a protein called E-cadherin, which normally acts like glue holding cells together. Without it, lobular cancer cells don’t clump into a firm, obvious mass the way ductal cancer cells do. Instead, they tend to grow in thin, single-file lines that weave through breast tissue. This growth pattern is the root of many of ILC’s unique challenges, from how hard it is to detect to where it spreads in the body.
About 95 percent of ILC tumors are estrogen receptor positive, meaning they rely on estrogen to grow. They also typically produce low or no HER2 protein. This hormone-driven profile is actually good news in one sense: it means the cancer responds to hormone-blocking therapies. But it also contributes to the risk of late recurrence, because hormone receptor-positive cancers can lie dormant for years before reactivating.
Why ILC Is Harder to Find on Imaging
One of the most clinically significant issues with ILC is how often standard mammography misses it. Because the cancer doesn’t form a dense, round lump, it can blend into surrounding breast tissue on a mammogram. The false-negative rate for ILC on standard 2D mammography has been reported as high as 43 percent, with breast radiologists estimating the modality’s sensitivity for lobular cancer at roughly 50 percent.
MRI performs substantially better, with an estimated sensitivity around 90 percent. Other imaging tools fall somewhere in between: contrast-enhanced mammography and molecular breast imaging are estimated at about 80 percent sensitivity, digital breast tomosynthesis (3D mammography) around 70 percent, and ultrasound around 60 percent. This detection gap matters because tumors that are harder to see tend to be diagnosed at a later stage or at a larger size, which directly affects treatment options and outcomes.
Survival Rates and Long-Term Outlook
For the first five years after diagnosis, ILC often has a prognosis comparable to or even slightly better than ductal breast cancer. In a large study, the cumulative rate of death specifically from ILC was 3.1 percent at three years, 6.2 percent at five years, and 12.2 percent at ten years. The overall 10-year survival rate, including deaths from all causes, was 73.7 percent.
Where ILC diverges from ductal cancer is in the long game. Hormone receptor-positive breast cancers in general carry a risk of late recurrence, but this pattern is especially pronounced in ILC. A substantial number of patients with early-stage ILC will relapse as late as 20 years after their initial diagnosis and treatment. Recurrences can appear anywhere from a few months to two decades out. This extended timeline is one of the reasons ILC requires long-term monitoring and often prolonged hormone-blocking therapy.
Unusual Patterns of Spread
Like other breast cancers, ILC most commonly spreads to lymph nodes, bones, lungs, and liver. But it also has a well-documented tendency to metastasize to sites that are unusual for breast cancer: the gastrointestinal tract, the peritoneum (the lining of the abdominal cavity), and the ovaries. These atypical metastases can cause symptoms that mimic entirely different diseases, such as ovarian cancer or a gastrointestinal condition, which sometimes delays the correct diagnosis.
This pattern of spread appears to be related to the loss of E-cadherin. Without that cell-adhesion protein, lobular cancer cells move differently through the body and seem to have an affinity for tissues that ductal cancer cells don’t typically target.
Surgical Challenges
The same diffuse growth pattern that makes ILC hard to see on imaging also makes it harder to remove completely during surgery. Because the cancer infiltrates tissue in thin strands rather than forming a discrete mass, surgeons sometimes have difficulty determining exactly where the tumor ends. In a 2022 study of 357 patients, 10.6 percent had positive margins (cancer cells at the edge of the removed tissue) after mastectomy, and for larger tumors the rate climbed to 18.7 percent. Positive margins often mean additional surgery is needed.
This is one reason MRI is frequently recommended before surgery for ILC. It gives a more accurate picture of the tumor’s true size and extent, which helps surgical planning and reduces the likelihood of needing a second operation.
How ILC Is Treated
Because the vast majority of ILC tumors are hormone receptor positive, hormone-blocking therapy is the cornerstone of treatment after surgery. For postmenopausal patients, aromatase inhibitors are typically used to block estrogen production. Research from a clinical trial comparing two types of aromatase inhibitors found that the specific choice may matter more for lobular cancer than for ductal cancer. Patients with ILC who received anastrozole (a nonsteroidal aromatase inhibitor) had better overall survival than those who received exemestane (a steroidal version), a difference that was not observed in ductal cancer patients.
Given the prolonged risk of late recurrence, many patients with ILC are now offered extended hormone therapy beyond the traditional five-year course, sometimes for 10 years or longer. Chemotherapy may also be part of the treatment plan depending on the stage and specific tumor characteristics, though hormone-positive, HER2-negative cancers like most ILC cases tend to be less responsive to chemotherapy than other subtypes.
Genetic Risk Factors
Most cases of ILC occur sporadically, without a clear inherited cause. However, inherited mutations in the CDH1 gene (the gene responsible for making E-cadherin) are strongly linked to ILC. People who carry a pathogenic CDH1 mutation have up to a 50 percent lifetime risk of developing lobular breast cancer. CDH1 mutations also cause hereditary diffuse gastric cancer syndrome, so families with a history of both stomach and lobular breast cancer may benefit from genetic testing.
Interestingly, the most commonly identified gene mutation in ILC patients overall is actually BRCA2, not CDH1. This likely reflects the fact that BRCA2 mutations are far more common in the general population, even though CDH1 mutations carry a much higher specific risk for lobular cancer.
What the Long-Term Picture Looks Like
ILC is serious, but it is also highly treatable when caught at an early stage. The combination of surgery, hormone therapy, and radiation (when appropriate) gives most patients a strong chance of long-term survival. The factors that make ILC uniquely challenging are its detection difficulty, its potential for late recurrence, and its unusual metastatic behavior. These are the reasons that follow-up after ILC tends to be longer and more vigilant than for some other breast cancer types, and why awareness of new or unusual symptoms remains important well beyond the five-year mark that many people think of as the “all clear” point.